MarketCapExport financials
Travere Therapeutics (TVTX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Travere Therapeutics Income Statement 2025-2010 | TVTX
Brief overview of income trends at Travere Therapeutics
The comparison covers a five-year financial horizon. According to figures from Travere Therapeutics, revenue changed from $198 million to $491 million over five years. The cumulative result was +147.4%, corresponding to roughly 19.9% per year. The pace indicates confident and sustained business growth.
Gross profit changed from $192 million to $480 million (+149.9%). The cost base moved more slowly than the top line, which supported margins. Comparing the endpoints gives gross margins of 96.9% and 97.9%. There was no meaningful shift in gross profitability.
The operating result measured by EBITDA moved from −$152 million to −$2.1 million, or +98.6%. The operating result developed less favorably than sales. EBITDA margin was −76.4% at the start and −0.4% at the end. Higher profitability strengthens the quality of operating growth.
Net income moved from −$169 million at the start to −$25.5 million at the end. The negative result improved without reaching break-even.
Market value was $1.2 billion at the start and $2.6 billion at the end. The market broadly confirmed the positive direction of the business.
Financial takeaway
The figures do not all move in the same direction. Key strengths include sales growth, steady gross profitability and positive operating leverage. The overall view is constrained by limited operating profitability. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Travere Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
2.58 B | 2.28 B | 613 M | 1.38 B | 1.65 B | 1.2 B | - | - | - | - | - | - | - | - | - | - |
Shares |
89.2 M | 78.9 M | 74.3 M | 63.8 M | 59.8 M | 47.5 M | - | - | - | - | - | - | - | - | - | - |
Historical Prices |
29 | 29 | 8.25 | 21.7 | 27.5 | 25.2 | 15.5 | 21.6 | 23.9 | 19.6 | 15 | 12.8 | 10.6 | 4.5 | - | - |
Net Income |
-25.5 M | -322 M | -111 M | -278 M | -180 M | -169 M | -146 M | -103 M | -59.7 M | -47.9 M | 117 M | -111 M | -33.8 M | -14.8 K | -23 K | - |
Revenue |
491 M | 233 M | 145 M | 109 M | 132 M | 198 M | 175 M | 164 M | 155 M | 134 M | 99.9 M | 28.2 M | - | - | - | - |
Cost of Revenue |
10.3 M | 7.74 M | 11.4 M | 4.42 M | 3.82 M | 6.13 M | 5.23 M | 5.53 M | 3.6 M | 4.55 M | - | - | 4.27 M | 18.1 M | - | - |
Gross Profit |
- | - | - | - | - | - | 170 M | 159 M | 151 M | 129 M | 97.7 M | 27.6 M | - | - | - | - |
Operating Income |
-62.8 M | -324 M | -388 M | -320 M | -199 M | -176 M | -137 M | -80 M | -53.8 M | -58.2 M | -50.7 M | -79.8 M | -24.8 M | -30.3 M | - | - |
Interest Expense |
11.6 M | -3.32 M | 11.3 M | 11 M | 19.7 M | 19.1 M | 18.8 M | 9.81 M | 4.42 M | 4.73 M | 7.7 M | 7.4 M | - | 84.1 K | - | - |
EBITDA |
-2.08 M | -280 M | -350 M | -299 M | -187 M | -152 M | -94.5 M | -61.6 M | -32.4 M | -42.1 M | -32.6 M | -74.4 M | -14 M | -12.8 K | -12.7 K | - |
Operating Expenses |
- | - | - | - | - | - | 285 M | 239 M | 202 M | 187 M | 144 M | 107 M | - | - | - | - |
General and Administrative Expenses |
337 M | 264 M | 266 M | 198 M | 126 M | 136 M | 129 M | 104 M | 104 M | 98 M | 79.5 M | 59.6 M | 16.9 M | 12.8 K | 12.7 K | - |
All numbers in USD currency
Quarterly Income Statement Travere Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
93.5 M | 91.9 M | 89.2 M | 88.9 M | 88.4 M | 87.5 M | 77.8 M | 77.5 M | 77.1 M | 75.4 M | 76.3 M | 76 M | 68.2 M | 64.3 M | 64 M | 63.6 M | 63.1 M | 62.5 M | 60.8 M | 60.6 M | 56.3 M | 52.2 M | 50.9 M | 44.8 M | 43.1 M | 43.1 M | 42.9 M | 42 M | 41.4 M | 41.4 M | 40.7 M | 40.1 M | 39.7 M | 39.4 M | 38.7 M | 39 M | 38 M | 37.9 M | 37 M | 36.7 M | 36.5 M | 36.5 M | 35.7 M | 35 M | 27.2 M | 26 M | 26.7 M | 25.6 M | 23.3 M | 18.4 M | 15.4 M | 12.3 M | 10.7 M | 107 K | 3.51 M | 3.06 M | 2.5 M | 107 K | 107 K | 107 K | - |
Net Income |
-34.8 M | -37.1 M | 25.7 M | -12.8 M | -41.2 M | - | -54.8 M | -70.4 M | -136 M | - | 151 M | -85.6 M | -86.3 M | - | -69.7 M | -67 M | -76 M | - | -35.6 M | -39 M | -53.9 M | -122 M | -22.5 M | -26.1 M | 808 K | -30.3 M | -36.5 M | -38.7 M | -41 M | -7.46 M | -54.5 M | -22.3 M | -18.4 M | -17.6 M | -17.8 M | -13.2 M | -11.1 M | -8.6 M | -37.1 M | -13.4 M | 11.2 M | -2.47 M | 106 M | -25.5 M | 39.7 M | -29 M | -18 M | 11.8 M | -75.7 M | -12.8 M | -12 M | -4.92 M | -4.87 M | -3.66 K | -30.3 M | -30.3 M | -30.3 M | -3.52 K | -10.6 K | -7.05 K | - |
Revenue |
170 M | 127 M | 165 M | 114 M | 81.7 M | - | 62.9 M | 54.1 M | 41.4 M | - | 37.1 M | 32.2 M | 30.9 M | - | 28.1 M | 54.2 M | 48.5 M | - | 68.2 M | 54.6 M | 47.4 M | 51 M | 51.1 M | 48.4 M | 47.8 M | 46.7 M | 44.4 M | 44.7 M | 39.6 M | 43.8 M | 40.7 M | 41.3 M | 38.4 M | 42.2 M | 40.3 M | 38.8 M | 33.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
2.17 M | 1.95 M | 1.58 M | 1.52 M | 4.68 M | - | 1.63 M | 2.06 M | 1.5 M | - | 1.29 M | 1.45 M | 4.14 M | - | 1.11 M | 2.05 M | 2.14 M | - | 1.59 M | 1.65 M | 1.64 M | - | 1.19 M | 1.49 M | 1.37 M | - | 1.51 M | 979 K | 1.02 M | - | 1.13 M | 1.18 M | 1.61 M | - | 925 K | - | - | - | - | - | - | - | - | - | - | - | - | 3.85 M | 2.08 M | - | - | 358 K | 930 K | - | - | - | - | - | - | - | - |
Operating Income |
3.95 M | -36.9 M | 24.9 M | -12.6 M | -42.7 M | - | -56.1 M | -67.7 M | -139 M | - | -92.6 M | -104 M | -97.4 M | - | -82.6 M | -65.5 M | -66.1 M | - | -31.7 M | -35.3 M | -47.5 M | -119 M | -19.4 M | -23.1 M | -15.1 M | -28.2 M | -34.4 M | -36.5 M | -38.2 M | -4.98 M | -35.6 M | -21.6 M | -17.9 M | -15.2 M | -10.6 M | -13.6 M | -14.4 M | -18.2 M | -20.4 M | -11.4 M | -8.24 M | -15.2 M | -20.5 M | -6.94 M | -8.1 M | -18.7 M | -21.9 M | -17.2 M | -22.1 M | -11.9 M | -6.03 M | -4.98 M | -1.89 M | - | -8.46 M | -4.74 M | -3.56 M | - | - | - | - |
Interest Expense |
-169 K | -91 K | 487 K | -526 K | 549 K | - | 520 K | -3.5 M | 238 K | - | 335 K | -201 K | 2.9 M | - | 2.8 M | 3 M | 2.5 M | - | 654 K | 216 K | -1.09 M | - | 553 K | 426 K | -190 K | - | -496 K | 125 K | -302 K | - | -90 K | -403 K | 121 K | - | 557 K | 382 K | 126 K | - | 151 K | -206 K | 210 K | 2.21 M | -314 K | 522 K | 311 K | -10.3 M | 2.6 M | -2.18 M | - | -874 K | - | -5 | -41.6 K | 500 | 26.8 K | -26.5 K | -17.3 K | 500 | 1.5 K | 1 K | - |
EBITDA |
33.4 M | -11.7 M | 67.5 M | 1.05 M | -29.9 M | - | -45.3 M | -57.8 M | -129 M | - | -81.7 M | -93.6 M | -90.7 M | - | -77.5 M | -57.9 M | -59 M | - | -11.1 M | -29.2 M | -41.5 M | -119 M | -1.49 M | -11.6 M | -9.41 M | -28.2 M | -19.3 M | -26.8 M | -33.3 M | -4.98 M | -21.8 M | -12.6 M | -13.6 M | -15.2 M | 2.73 M | -4.88 M | -10.1 M | -18.2 M | -8.42 M | -3.52 M | -4.35 M | -15.2 M | -11.1 M | -1.41 M | -6.32 M | -18.7 M | -18.3 M | -15.5 M | -21.9 M | -11.9 M | -5.87 M | -4.88 M | -1.83 M | - | -8.39 M | -4.7 M | -3.56 M | - | - | - | - |
Operating Expenses |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.8 M | - | 78.8 M | 81.2 M | 77.8 M | 48.8 M | 76.3 M | 62.9 M | 56.3 M | 57.4 M | 50.9 M | 52.4 M | 48 M | 55.5 M | 54.3 M | 44.7 M | 37.2 M | 45.7 M | 48.5 M | 31 M | 25.5 M | 32.8 M | 30.2 M | 22.9 M | 22.1 M | 11.9 M | 5.15 M | 5.1 M | 1.89 M | - | 8.46 M | 4.74 M | 3.56 M | - | - | - | - |
General and Administrative Expenses |
96.1 M | 80.3 M | 86.5 M | 76.2 M | 72.8 M | - | 65.6 M | 64.8 M | 64.2 M | - | 67.8 M | 68.2 M | 66 M | - | 52.4 M | 53 M | 46.8 M | - | 36.1 M | 35 M | 36.8 M | - | 32 M | 35 M | 33.1 M | - | 29.8 M | 39 M | 32.7 M | - | 26.1 M | 25.1 M | 26.5 M | - | 24.9 M | 28.8 M | 23.1 M | - | 23.5 M | 23.2 M | 19.1 M | - | 22.3 M | 19.7 M | 14.9 M | - | 17.4 M | 9.58 M | 15.1 M | - | 2.97 M | 4.49 M | 1.73 M | 3.16 K | 3 K | 3.01 K | 80.2 K | 3.02 K | 9.07 K | 6.05 K | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Travere Therapeutics (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.